TUMOR MUTATION BURDEN ALONE OR IN COMBINATION WITH IMMUNE MARKERS AS BIOMARKERS FOR PREDICTING RESPONSE TO TARGETED THERAPY

摘要

The invention relates to the use of biomarkers for predicting the response to cancer (e.g. melanoma) treatments, for selecting a treatment for a cancer patient (e.g. using targeted therapy, e.g. using a BRAF and/or MEK inhibitor), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.